Your cart is currently empty!

ISO 21560:2020
ISO 21560:2020 General requirements of tissue-engineered medical products
CDN $115.00
Description
This document specifies general requirements for tissue-engineered medical products (TEMPs), which are used in regenerative medicine. With regard to safety, this document outlines requirements for materials, manufacture, quality control, and unintentional biological effects elicited by TEMPs. This document does not address requirements for clinical trials and efficacy.
This document is not applicable to tissue-engineered products used for diagnosis, ex-vivo testing or extracorporeal treatments of patients (e.g. dialysis with TEMP components). TEMPs containing viable xenogenic cells, genetically modified cells, or cells derived from abnormal cells or tissues (e.g. cancerous tissues) are also excluded from the scope. The combination of TEMPs with medical devices, with the exception of scaffolds comprised of synthetic and/or naturally-derived (e.g. animal sourced) materials, is also excluded from the scope.
NOTE International, national or regional regulations or requirements, or the Pharmacopeia also apply to specific topics covered in this document.
Edition
1
Published Date
2020-08-31
Status
PUBLISHED
Pages
11
Format 
Secure PDF
Secure – PDF details
- Save your file locally or view it via a web viewer
- Viewing permissions are restricted exclusively to the purchaser
- Device limits - 3
- Printing – Enabled only to print (1) copy
See more about our Environmental Commitment

Abstract
This document specifies general requirements for tissue-engineered medical products (TEMPs), which are used in regenerative medicine. With regard to safety, this document outlines requirements for materials, manufacture, quality control, and unintentional biological effects elicited by TEMPs. This document does not address requirements for clinical trials and efficacy.
This document is not applicable to tissue-engineered products used for diagnosis, ex-vivo testing or extracorporeal treatments of patients (e.g. dialysis with TEMP components). TEMPs containing viable xenogenic cells, genetically modified cells, or cells derived from abnormal cells or tissues (e.g. cancerous tissues) are also excluded from the scope. The combination of TEMPs with medical devices, with the exception of scaffolds comprised of synthetic and/or naturally-derived (e.g. animal sourced) materials, is also excluded from the scope.
NOTE International, national or regional regulations or requirements, or the Pharmacopeia also apply to specific topics covered in this document.
Previous Editions
Can’t find what you are looking for?
Please contact us at:
Related Documents
-
ISO 27185:2012 Cardiac rhythm management devices – Symbols to be used with cardiac rhythm management device labels, and information to be supplied – General requirements
0 out of 5CDN $273.00 Add to cart -
ISO 5840:2025 Cardiovascular implants – Cardiac valve prostheses – Part 2: Surgically implanted heart valve substitutes – Amendment 1
0 out of 5CDN $32.00 Add to cart -
ISO 29783:2016 Prosthetics and orthotics – Vocabulary – Part 3: Pathological gait (excluding prosthetic gait)
0 out of 5CDN $76.00 Add to cart -
ISO 14708:2020 Implants for surgery – Active implantable medical devices – Part 5: Circulatory support devices
0 out of 5CDN $351.00 Add to cart